Last reviewed · How we verify
NCT03155022: CARIOCA
Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction
NA trial testing Remote ischemic conditioning and intracoronary ischemic conditioning in Myocardial Infarction, Acute in 750 participants. Completed in 3 October 2023.
3 October 2023
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 750 |
| Start date | 12 April 2018 |
| Primary completion | 3 October 2023 |
| Estimated completion | 3 October 2023 |
| Sites | 4 locations across Belgium, France |
Drugs / interventions tested
- Remote ischemic conditioning and intracoronary ischemic conditioning
- Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning
Conditions studied
- Myocardial Infarction, Acute — all drugs for Myocardial Infarction, Acute →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Myocardial Infarction, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Infarct size is a major determinant of prognosis after AMI. Evidence indicates that the combination of intracoronary ischemic conditioning (ICIC) and remote ischemic conditioning (RIC) can significantly reduce infarct size in STEMI patients. Whether the combination of these two interventions may improve clinical outcome after STEMI remains unknown. The objective of the present study is to determine whether combination of ICIC and RIC can improve STEMI patients clinical outcome at 6 months.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, et al · · 2023 · cited 106× · PMID 36753049 · DOI 10.1124/pharmrev.121.000348 -
Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration.
Caccioppo A, Franchin L, Grosso A, Angelini F, et al · · 2019 · cited 50× · PMID 31614414 · DOI 10.3390/ijms20205024 -
Reperfusion injury in STEMI: a double-edged sword.
Thomas KS, Puthooran DM, Edpuganti S, Reddem AL, et al · · 2025 · cited 4× · PMID 40911117 · DOI 10.1186/s43044-025-00683-7 -
Remote ischemic conditioning in intensive care: From bench to bedside.
Benghanem S, Stiel L, Jouan Y, Vedrenne-Cloquet M, et al · · 2026 · PMID 41788501 · DOI 10.1016/j.aicoj.2025.100018
Verify or expand the search:
- PubMed search for NCT03155022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myocardial Infarction, Acute
Currently open trials in the same condition.
- NCT07181317 — WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up · recruiting
- NCT07008391 — High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS · NA · recruiting
- NCT05759078 — Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Defici · Phase 4 · recruiting
- NCT05198791 — Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries. · Phase 2 · recruiting
- NCT04968808 — Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI) · NA · recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03155022 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03155022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing